Previous 10 | Next 10 |
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BeyondSpring Inc. (NASDAQ: BYSI) please note that in the fifth paragraph of the release, the correct percentage in the second sentence is 40.9, not 37.5 as previousl...
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a New York-based global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that,...
NEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its fourth-...
Deals and Financings Ping An (PNGAY), a China insurance company, announced a $311 million agreement with Japan's Shionogi to develop new drugs for infectious diseases and CNS needs based on Ping An's lifestyle data. For its $311 million, Ping An will receive a 2% stake in Shionogi shares. Th...
- Potential to be First Superior Therapy to Standard of Care for Chemotherapy-Induced Neutropenia in 30 Years - - Targeting CIN After All Chemotherapies in All Cancer Types in Combination with All G-CSFs - - Strong Patent Protection Through 2036 - NEW YORK, March 30, 20...
- New Data to be Presented at NCCN 2020 Annual Conference - NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immun...
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the submission of a ...
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that new clinical dat...
Arcturus Therapeutics (NASDAQ: ARCT ) initiated with Buy rating and $19 (70% upside) price target at Guggenheim. More news on: Arcturus Therapeutics Holdings Inc., BeyondSpring Inc., Millendo Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the appointments of D...
News, Short Squeeze, Breakout and More Instantly...
COPT Defense Properties of Beneficial Interest (CDP) is expected to report $0.64 for Q2 2024 Bank of Marin Bancorp (BMRC) is expected to report $0.19 for Q2 2024 Oak Ridge Financial Services Inc (BKOR) is expected to report for Q2 2024 D/B/A Centerspace (CSR) is expected to report $1....
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 12.4% to $0.0886 on volume of 1,366,648,994 shares Ascent Solar Technologies Inc (ASTI) rose 63.4% to $0.2147 on volume of 656,794,712 shares Pineapple Energy Inc. (PEGY) rose 61.4% to $...
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it hosted a virtua...